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Global impact of COVID-19 on
stroke care
SVIN COVID-19 global registry
Abstract
Background: The COVID-19 pandemic led to profound changes in the organization of health care systems worldwide.
Aims: We sought to measure the global impact of the COVID-19 pandemic on the volumes for mechanical thromb-
ectomy, stroke, and intracranial hemorrhage hospitalizations over a three-month period at the height of the pandemic
(1 March–31 May 2020) compared with two control three-month periods (immediately preceding and one year prior).
Methods: Retrospective, observational, international study, across 6 continents, 40 countries, and 187 comprehensive
stroke centers. The diagnoses were identified by their ICD-10 codes and/or classifications in stroke databases at
participating centers.
Results: The hospitalization volumes for any stroke, intracranial hemorrhage, and mechanical thrombectomy were
26,699, 4002, and 5191 in the three months immediately before versus 21,576, 3540, and 4533 during the first three
pandemic months, representing declines of 19.2% (95%CI, 19.7 to 18.7), 11.5% (95%CI, 12.6 to 10.6), and 12.7%
(95%CI, 13.6 to 11.8), respectively. The decreases were noted across centers with high, mid, and low COVID-19
hospitalization burden, and also across high, mid, and low volume stroke/mechanical thrombectomy centers. High-
volume COVID-19 centers (20.5%) had greater declines in mechanical thrombectomy volumes than mid- (10.1%)
and low-volume (8.7%) centers (p< 0.0001). There was a 1.5% stroke rate across 54,366 COVID-19 hospitalizations.
SARS-CoV-2 infection was noted in 3.9% (784/20,250) of all stroke admissions.
Conclusion: The COVID-19 pandemic was associated with a global decline in the volume of overall stroke hospital-
izations, mechanical thrombectomy procedures, and intracranial hemorrhage admission volumes. Despite geographic
variations, these volume reductions were observed regardless of COVID-19 hospitalization burden and pre-pandemic
stroke/mechanical thrombectomy volumes.
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Introduction
In December 2019, a novel highly pathogenic virus,
severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), caused an infectious disease involving
multiple organ systems termed coronavirus disease
2019 (COVID-19). COVID-19 holds a unique balance
between high transmissibility and low-to-moderate
morbidity and mortality that has led to a nearly uni-
versal spread with devastating consequences world-
wide. On 11 March 2020, the World Health
Organization declared a global pandemic as COVID-
19 hospitalizations and emergency medical system acti-
vations increased. As a potential consequence of its
neurotropism as well as the inflammatory,
immunological, and coagulation disorders, COVID-19
has been reported in association with a broad array of
neurological disorders including encephalitis, Guillain-
Barre syndrome, seizures, ischemic, and hemorrhagic
strokes.1 Some groups reported an increase in crypto-
genic strokes involving young patients with
SARS-CoV-2 infection, possibly in association with
endothelial inflammation and thrombotic diathesis.2–7
Others reported a decline in the rates of stroke hospi-
talizations and the proportion of patients receiving
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reperfusion therapies (intravenous thrombolysis (IVT)
and/or mechanical thrombectomy (MT)) for acute
ischemic stroke (AIS). Notably, many of these studies
originated from global epicenters for the pandemic sup-
porting the notion that the indirect or collateral
damage of COVID-19 on systems of care has had a
greater impact on stroke patients than the viral infec-
tion itself.3,5,8–12 However, most of these reports were
limited to regional or country-specific analyses, and
thus, the extent to which the COVID-19 outbreak has
impacted global stroke systems of care has not been
previously assessed. Importantly, given the profound
benefit of MT in AIS, the global public health impact
of such declines, if confirmed, adds to the devastation
caused by COVID-19.
Aims and hypotheses
We conducted an international, observational study
on the impact of the COVID-19 pandemic on
stroke care at the height of the COVID-19 pandemic.
Our primary aim was to evaluate the effect of
COVID-19 on stroke care as measured by the
changes in volumes for overall stroke hospitaliza-
tions, ischemic stroke/transient ischemic attacks
(TIA) admissions, ICH admissions, and MT proced-
ures across the pre-pandemic and pandemic periods
in a multinational pool of comprehensive stroke cen-
ters (CSC). The study compared the three initial
months of the pandemic (1 March 2020–31 May
2020) with (1) the immediately preceding months
(December 2019–February 2020 for overall volume
and November 2019–February 2020 for monthly
volume) as the primary analysis and (2) the equiva-
lent three months in the previous year (1 March
2019–30 May 2019) as the secondary analysis. The
reason for this analytic hierarchy was an a priori
expectation that the volumes for both stroke admis-
sions and MT procedures would increase over time
due to the growing evidence supporting the broader
utilization of MT.13–15 While the primary analysis
provided a realistic picture of stroke care utilization
prior to COVID-19, the secondary analysis allowed
for the assessment for potential seasonal variations.16
We hypothesized that in the face of the pandemic’s
strain on healthcare infrastructure, (1) a reduction in all
four aforementioned measurements of stroke care
would take place over the pandemic, (2) centers with
higher COVID-19 inpatient volumes would report
greater decreases in stroke admissions and MT proced-
ure volumes, (3) the degree of decline in stroke admis-
sions and MT procedure volumes would be less
profound in high-volume compared to low-volume
stroke centers, and (4) a geographic variation would
exist in the intensity of decline in stroke care.
Methods
Data are available upon request to the corresponding
author.
Study design
This was a cross-sectional, observational, retrospective
study evaluating monthly and weekly volumes of con-
secutive patients hospitalized with a diagnosis of
COVID-19, stroke, MT, and ICH. The diagnoses
were identified by their related ICD-10 codes (primary,
secondary, or tertiary discharge codes) and/or classifi-
cations in stroke databases at participating centers.
Setting and participants
Data were collected from collaborators of the Society of
Vascular and Interventional Neurology, the Middle East
North Africa Stroke and Interventional Neurotherapies
Organization, the Japan Society of Vascular and
Interventional Neurology, and academic partners from
6 continents, 40 countries, and 187 CSCs. To reduce
bias, only centers providing the full dataset required
for any given analysis were included in that specific ana-
lysis. Centers were screened for potential confounders
that could explain unexpected changes in volumes. One
center in Vietnam was excluded from the MT secondary
analysis due to an abrupt increase in volume attributed
to the purchase of automated imaging software. One
center in Brazil was excluded from the stroke admission
analysis because it became the designated center for
stroke patients, resulting in tripling of their volumes.
Study variables and outcomes measures
The overall and mean monthly volumes for stroke hos-
pitalizations, admissions for ischemic stroke/TIA, and
admissions for ICH andMT procedures were compared
across the pandemic and pre-pandemic periods for the
overall population and across the low, mid, and high
volume strata based on mean monthly volume tertiles
for COVID-19 hospitalizations (10.6 vs. >10.6–103.6
vs. >103.6 COVID-19 admissions/month), stroke
admissions (46.2 vs. >46.2–78.4 vs. >78.4 stroke
admissions/month), and MT interventions (4.8 vs.
>4.8 to 11.4 vs. >11.4 procedures/month).
Statistical analysis
We first compared overall hospital volumes for stroke
admissions (overall stroke, ischemic, and ICH) and MT
procedures between the pre-pandemic and the pan-
demic period. For this analysis, the percentage change
in the number of admissions or procedures between the
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two time periods was calculated. The three-month pre-
pandemic period was restricted to three months before
the pandemic (1 December 2019–29 February 2020) to
keep it consistent with the three months during the
COVID-19 pandemic group (1 March 2020–31 May
2020). The 95% confidence intervals for percentage
change were calculated using the Wilson procedure
without continuity correction. The analyses were
repeated within each tier (low, mid, and high) of centers
classified based on COVID-19 hospitalizations, stroke
admissions, and MT procedures. The relative percent-
age change in overall volume between low, mid, and
high-volume centers was tested using the z-test of pro-
portion. We also looked at relative change in overall
volume by continent.
In the second analysis, we compared monthly hos-
pital volumes (admissions or procedures/hospital/
month) for our outcome of interests between the
pre-pandemic and the pandemic period. For the pre-
pandemic period, for each hospital, the monthly hos-
pital volume was calculated from November 2019 to
February 2020 and compared to the monthly hospital
volume during the pandemic period (1 March 2020–31
May 2020). The data were analyzed in a mixed design
using a repeated-measures analysis of variance (PROC
MIXED analysis in SAS) to account for the paired data
structure and potential covariates. The auto-regressive,
compound symmetrical, and unstructured variance-
covariance matrix structures were analyzed for the
best model determined by Akaike’s Information
Criterion. The unstructured matrix was the best fit
and used for most analyses. The monthly hospital
volume analysis was adjusted for peak COVID-19
volume for each country and the continent. Estimated
marginal means were calculated using the LSMEANS
statement in PROC MIXED. Similar to the overall
volume analysis, monthly volume analysis was repeated
within low, mid, and high tier of centers based on their
COVID-19 hospitalizations, stroke admissions, and
MT procedures as well as by the continent.
Finally, for our secondary objective, we compared
the relative change in overall volume and change in
monthly hospital volume during the COVID-19 pan-
demic and corresponding three months from 2019 (1
March 2019–31 May 2019). All data were analyzed
using SAS version 9.4 (SAS Institute), and the signifi-
cance level was set at a p-value of <0.05.
Funding and ethics
This was an investigator-initiated project with no fund-
ing. The first and last authors wrote the first draft of the
manuscript with subsequent input of all co-authors.
The institutional review boards from the coordinating
sites (Emory University and Boston University)
considered that the investigators did not have access
to protected health information, and thus no IRB over-
sight was required since the study did not meet the fed-
eral description of human subject research. This study
is reported in accordance with the Strengthening the
Reporting of Observational studies in Epidemiology
(STROBE) statement.
Results
A total of 16,141, 26,699, and 21,576 stroke hospital-
izations (overall n ¼ 64,416) and 3397, 5191, and 4533
MT procedures (overall n¼ 13,121) were included
across the three-month prior year, three-month imme-
diately pre-pandemic, and three-month pandemic peri-
ods, respectively.
Overall stroke hospitalization volumes
In the primary analysis of overall volume, stroke hos-
pitalization volumes were 26,699 admissions in the
three months immediately before compared to 21,576
admissions during the pandemic, representing a 19.2%
(95%CI, 19.7 to 18.7, N¼ 121 sites) drop, Table 1.
The stroke hospitalization decline had a geographic
variation: Asia, 20.5% (95%CI, 21.2 to 19.8);
North America, 20.6% (95%CI, 21.4 to 19.7);
Europe, 11.2% (95%CI, 12.3 to 10.1);
South America, 15.9% (95%CI, 17.9 to 14.0);
Oceania, 11.6% (95%CI, 14.4 to 9.3); Africa,
48.1% (95%CI, 55.8 to 40.5), Table S1. In an
analysis of monthly volume, after adjustment for peak
COVID-19 volume by country and continent, the
number of hospitalizations for stroke/month/hospital
(adjusted mean (SE)) declined from 76.4 (12.3) pre-
pandemic to 64.2 (12.0) during the pandemic
(p< 0.0001), Table 1.
Mechanical thrombectomy procedural volumes
MT volume data was represented by 176 centers in the
primary analysis with 5191 procedures in the three
months immediately preceding compared to 4533 pro-
cedures during the first three months of the pandemic,
representing a 12.7% (95%CI, 13.6 to 11.8) decline,
Table 2. The volume reduction varied: Asia, 9.8%
(95%CI, 11.3 to 8.4); North America, 14.5%
(95%CI, 16.2 to 12.9); Europe, 14.4% (95%CI,
16.4 to 12.6); South America, 12.4% (95%CI,
19.0 to 7.9), Oceania, 9.4% (95%CI, 13.4 to
6.5); Africa, 21.2% (95%CI, 37.8 to 10.7),
Table S2. The adjusted mean (SE) number of MT pro-
cedures/month/center decreased from 10.9 (1.3) pre-
pandemic to 9.8 (1.3) during the pandemic
(p< 0.0001), Table 2. There were 120 centers that
International Journal of Stroke, 0(0)
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Table 1. Stroke admissions overall and monthly volumes immediately before and during the COVID-19 pandemic




Immediately before During COVID-19
p% (95%CI) Adjusted mean (SE)
Overall 119 26,699 21,576 –19.2 (19.7 – 18.7) 121 76.4 (12.3) 64.2 (12.0) <0.0001
Hospital COVID-19 volumeb
Low 38 7612 6654 12.6 (13.4 – 11.9) 38 62.4 (31.4) 53.9 (30.7) 0.002
Mid 31 7495 6008 19.8 (20.8 – 19.0) 34 84.8 (10.5) 71.0 (8.7) 0.002
High 30 7163 5534 22.7 (23.7 – 21.8) 33 90.1 (9.8) 72.9 (9.3) <0.0001
Hospital stroke volumec
Low 40 3536 3003 –15.1 (–16.3 – –13.9) 40 28.7 (2.6) 24.5 (2.5) <0.0001
Mid 37 6804 5609 –17.6 (–18.5 – –16.7) 40 62.7 (2.7) 53.1 (3.3) <0.0001
High 37 14,994 12,400 –17.3 (–17.9 – –16.7) 41 134.1 (21.6) 111.6 (20.8) <0.0001
N: number of hospitals; n1: number of admissions immediately before COVID-19 pandemic; n2: number of admissions during COVID-19 pandemic;
CI: confidence interval; SE: standard error.
Note: The n1 is based on 3 months before (December 2019–February 2020) COVID-19 pandemic.
aThe monthly volume analysis is adjusted for peak COVID-19 volume for each country and the continent.
bp: low vs. mid 0.0001; low vs. high 0.0001; mid vs. high 0.0001.
cp: low vs. mid ¼ 0.001; low vs. high ¼ 0.002; mid vs. high ¼ 0.588.
Table 2. Mechanical thrombectomy overall and monthly volumes immediately before and during the COVID-19 pandemic




Immediately before During COVID-19
p% (95%CI) Adjusted mean (SE)
Overall 176 5191 4533 12.7 (13.6 – 11.8) 173 10.9 (1.3) 9.8 (1.3) <0.0001
Hospital COVID-19 volumeb
Low 44 952 869 8.7 (10.7 – 7.1) 44 11.2 (3.6) 10.5 (3.5) 0.044
Mid 45 1370 1232 10.1 (11.8 – 8.6) 45 11.7 (1.2) 10.8 (1.2) 0.004
High 45 1602 1273 20.5 (22.6 – 18.6) 46 7.8 (2.2) 5.7 (2.2) <0.0001
Hospital MT volumec
Low 59 459 412 –10.2 (–13.4 – –7.8) 60 2.6 (0.36) 2.3 (0.36) 0.082
Mid 55 1294 1092 –15.6 (–17.7 – –13.7) 55 8.1 (0.46) 7.0 (0.50) 0.0002
High 58 3432 3029 11.7 (12.9 – 10.7) 58 18.8 (1.8) 16.8 (1.7) 0.0002
N: number of hospitals; n1: number of procedures immediately before COVID-19 pandemic; n2: number of procedures during COVID-19 pandemic;
CI: confidence interval; SE: standard error; MT: mechanical thrombectomy.
The n1 is based on three months before (December 2019–February 2020) COVID-19 pandemic.
aThe monthly volume analysis is adjusted for peak COVID-19 volume for each country and the continent.
bp: low vs. mid ¼ 0.259; low vs. high 0.0001; mid vs. high 0.0001.
cp: low vs. mid ¼ 0.004; low vs. high ¼ 0.345; mid vs. high ¼ 0.0003.
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reported concomitant monthly data on stroke admis-
sion and MT volume. The adjusted mean (SE) monthly
proportion of MT relative to stroke admissions
remained stable across the pre-pandemic and pandemic
periods (17.8 (2.2)% vs. 18.5 (2.2)%, respectively; p ¼
0.150). This proportional stability in MT performance
was consistent across all COVID-19 and MT hospital-
ization volumes strata, Table S3.
Ischemic stroke/TIA and intracranial hemorrhage
volumes
The ischemic stroke/TIA admission volumes declined
from 19,882 to 16,884 patients across the three months
preceding versus the pandemic months, corresponding
to a 15.1% (95%CI, 15.6 to 14.6, N¼ 113 sites)
reduction with an adjusted mean (SE) number of ische-
mic stroke or TIA/month/center decreasing from 64.3
(6.8) to 55.6 (6.5) across the two epochs (p< 0.0001).
Complete results are presented in Table S4.
The ICH admission volumes, submitted by 100 sites,
decreased from 4002 to 3540 patients across the three
months immediately before versus the pandemic
months, representing an 11.5% (95%CI, 12.6 to
10.6) decline with the adjusted mean (SE) number
of hospitalizations for ICH/month/center dropping
from 13.4 (2.6) to 11.6 (2.6) across the two periods
(p< 0.0001), Table S5.
Changes in stroke care metrics during the
pandemic as a function of COVID-19
hospitalization volumes
Figures 1 and 2 provide the weekly volume of stroke
admissions (ischemic and hemorrhagic), MT, and
COVID-19 hospitalizations. COVID-19 hospital
weekly volume data was available for 131 centers.
There was an early peak of 1235 COVID-19 hospital-
izations in February which predominantly originated
from one hospital in Wuhan, China. Significant reduc-
tions in the mean monthly volumes were seen for all
stroke care metrics across all tertiles of low, mid, and
high COVID-19 hospitalization volumes.
The exception was ICH volumes in high-volume
COVID-19 centers which did not show a statistically
significant difference (Tables 1, S4, and S5). High-
volume COVID-19 centers (20.5%; 95%CI, 22.6
to 18.6) had greater declines in MT volumes than
mid- (10.1%; 95%CI, 11.8 to 8.6; p< 0.0001)
and low-volume (8.7%; 95%CI, 10.7 to 7.1;
p< 0.0001) COVID-19 centers, Table 2. Likewise,
high-volume COVID-19 centers (22.7%; 95%CI,
23.7 to 21.8) had greater reductions in stroke hos-
pitalization volumes than mid- (19.8%; 95%CI,
20.8 to 19.0; p< 0.0001) and low-volume
(12.6%; 95%CI, 13.4 to 11.9; p< 0.0001)
COVID-19 centers, Table 1.
Changes in stroke care metrics during the
pandemic as a function of stroke center MT and
admission volumes
Significant declines in the mean monthly volumes were
observed for all stroke/MT metrics across low-, mid-,
and high-volume stroke/MT centers except MT vol-
umes in low-volume MT centers showed a trend in
decline (Tables 1, 2, S4, and S5). Mid-volume stroke
centers (17.6%; 95% CI, 18.5 to 16.7) demon-
strated greater decreases in stroke admission volumes
Figure 1. Weekly volume of stroke admissions (ischemic






























































































































































































































Ischemic Stroke, ICH vs COVID-19 admissions
Ischemic Stroke only ICH COVID Hospitalizaons
*
*Peak of 1235 COVID hospitalizations in the second week of February, predom-
inantly from one hospital in Wuhan, China.























































































































































































































Mechanical Thrombectomy vs COVID-19 Hospitalizaons
Mechanical Thrombectomy COVID Hospitalizaons
* 
*Peak of 1235 COVID hospitalizations in the second week of February, predom-
inantly from one hospital in Wuhan, China.
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than low-volume (15.1%; 95%CI, 16.3 to 13.9;
p< 0.0001) centers, Table 1.
Secondary objective
Table S6 depicts the volumes for overall stroke, ische-
mic stroke/TIA, ICH hospitalizations, and MT proced-
ures during the first three months of the pandemic
versus the corresponding period in the prior year.
Compared to the prior year, there were significant
declines in the monthly volumes for stroke and ischemic
stroke/TIA admissions but not for ICH and MT.
Associations between the diagnoses of COVID-19
and stroke
There were 124 centers that reported patients with con-
comitant stroke (all subtypes) and SARS-CoV-2 infec-
tion. To reduce bias, 13 centers with no COVID-19
patients were excluded, leaving 111 eligible centers. A
diagnosis of any stroke was present in 791 of 54,366
(1.45%; 95% CI 1.35–1.55) COVID-19 hospitaliza-
tions. There was geographic variation with incidences
ranging from 0.43% (95%CI 0.08–2.38) in Oceania to
11.9% in South America (95%CI 10.05–14.03), Table
S7. Conversely, 784 of the 20,250 (3.9%, 95% CI 3.61–
4.14) overall stroke admissions were diagnosed with
COVID-19 with proportions varying from 0.14%
(95%CI 0.03–0.78) in Oceania to 8.93% in South
America (95%CI 7.54–10.55), Table S8.
Discussion
We noted a significant global decline in all measured
stroke care metrics in the current study including the
numbers of mechanical thrombectomy procedures
(12.7%), overall stroke admissions (19.2%), ische-
mic stroke/TIA admissions (15.1%), and intracranial
hemorrhage hospitalization volumes (11.5%) during
the COVID-19 pandemic as compared to the immedi-
ately preceding three months, confirming our primary
hypothesis. Volume reductions were also seen in rela-
tion to the equivalent period in the prior year for stroke
admissions and ischemic/TIA admissions. The intensity
of the decline was more pronounced when comparing
the pandemic period with the immediate three months
prior than with the same months in 2019 (MT: 12.7%
vs. 6.0%; stroke admissions: 19.2% vs. 12%). This fol-
lowed our a priori expectations in face of the expan-
sions in MT indications along with its progressive but
gradual global implementation in developed and
developing countries.17 Interestingly, despite the abso-
lute decrease in MT volumes, the proportion of MT
relative to stroke admissions remained stable during
the pandemic. While at first glance this might suggest
that the intra-hospital workflow was maintained, it is
possible that this was not the case since one would
actually expect an increase in the MT ratio relative to
stroke admissions as many studies have now demon-
strated that there was a preferential decline in patients
presenting with milder strokes during the pan-
demic.4,11,18–20 The decreases in the amount of stroke
care were noted across centers with high, mid, and low
COVID-19 hospitalization burden and also across
high, mid, and low volume stroke and MT centers.
As hypothesized, centers with higher COVID-19 inpa-
tient volumes suffered more declines. Contrary to our
expectations, the declines in stroke hospitalizations and
MT volumes were more profound in mid-(and high-)
volume than low-volume stroke centers. This might be
related to the fact that larger centers were more likely to
become the preferred destination for COVID-19 refer-
rals leading to capacity issues. Finally, we confirmed a
broad geographic variation in the patterns of stroke
care decline.
Our results align with recent reports emphasizing the
collateral effects of the COVID-19 pandemic on stroke
systems of care from China,10,18 Spain,3,19 Italy,21,22
France,9,23 Germany,12 Brazil,20 Canada,24 and
United States,5,11,25,26 showing declines in the volumes
for MT, IVT, and stroke hospitalizations over the pan-
demic (Table S9–11). Some of these studies also
reported delays in hospital arrival times18,21,25 and
treatment workflow.9,21 Our analysis adds to the grow-
ing literature regarding the collateral damage of
COVID-19 on stroke care with the advantage of pro-
viding a broader global perspective. While the overall
data clearly points to a significant reduction in the
quantity of stroke care provided during the pandemic,
it also depicts variations within and across the different
regions reflecting the diversity in the epidemiology for
COVID-19 as well as in the socio-cultural behaviors,
healthcare logistics, and infrastructure encountered
across the globe. Indeed, our study demonstrated
important geographic variations in the proportional
declines for both stroke hospitalization and MT vol-
umes. Notably, our analysis may have underestimated
the impact of geographic disparities in healthcare
resources and related socio-economic factors as we
only included thrombectomy capable centers which
are known to have better infrastructure than the more
commonly found primary stroke centers. Moreover,
there was a higher geographic variation in the propor-
tional decline for stroke hospitalization (Asia, 20.5%;
North America, 20.6%; Europe, 11.2%; South
America, 15.9%, Oceania, 11.6%; Africa,
48.1%) than mechanical thrombectomy (Asia,
9.8%; North America, 14.5%; Europe, 14.4%;
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South America, 12.4%, Oceania, 9.4%; Africa,
21.2%) volumes. As seen in relation to the stability
in the MT ratio relative to stroke admissions, this might
have been related to the favored decline in milder
strokes over the course of the pandemic.4,11,18–20
Given the growing evidence supporting the association
between COVID-19 and thromboembolic events, it
would be expected that the stroke incidence would
rise at the precipice of the pandemic. Several factors
may explain this paradoxical global decrease in
stroke, MT, and ICH volumes observed in this study.
As this decline in stroke volume was seen in centers
with low or non-existent COVID-19 hospitalizations,
hospital access due to the COVID-19 hospitalization
burden was unlikely a major factor.12 As elective sur-
geries were canceled with the pandemic, a decrease in
perioperative stroke may have played a role. It is also
conceivable that the environmental situation of a lock-
down, with improved patient behaviors or medication
compliance, may be protective in decreasing vascular
events.27 A reduction in exposure to other common
viruses that may play a role in triggering vascular
events may have also reduced stroke risk. However, it
is unlikely that true incidence of stroke declined and
more likely the behavioral and infrastructural changes
related to the pandemic led to a reduction of admission
of AIS patients, especially during the initial phases of
public lockdown. Fear of contracting SARS-CoV-2
may have led many patients with milder stroke presen-
tations to avoid seeking medical attention.4,11,18–20
Physical distancing measures may have prevented
patients from the timely witnessing of a stroke.
Our subgroup of 111 centers including 54,366
COVID-19 hospitalizations is the largest sample report-
ing the concomitant diagnoses of stroke and SARS-
CoV-2 infection to date. Our 1.45% stroke rate in
COVID-19 hospitalizations is similar to the pooled
incidence of 1.1–1.2% (range, 0.9–2.7%) of hospita-
lized COVID-19 patients.28,29 Some variations in the
proportions are expected given the different definitions
(all strokes vs. ischemic only) and populations involved
(all hospitalized vs. severely infected only) across stu-
dies. We also provide a new perspective on this rela-
tionship by reporting an incidence of 3.9% (784/20,250)
for SARS-CoV-2 infection across all stroke admissions
among centers with documented COVID-19
hospitalization.
Study strengths and limitations
The strength of our study was the large volume of
patients (n¼ 64,416) and a high number of centers
(n¼ 187) contributing data from a diverse population
across six continents and 40 countries. Our study
contained centers with high and low COVID-19 hospi-
talization admissions, high and low stroke admission,
and MT volumes, permitting the generation of multiple
hypotheses and endpoints.
The limitations of this study were that the diagnosis
of stroke/TIA/ICH, thrombectomy volume in some
centers was obtained using hospital ICD administrative
codes, and verification for accurate diagnosis was not
universally undertaken. The centers contributing to
these data have systems in place to track stroke admis-
sions; thus, the relative changes in volume from this
analysis are likely accurate. Details on patient-level
data including demographics, stroke subtypes, and clin-
ical outcomes were not collected as these were not the
focus of the study. As with any other study, our data
may underestimate true rates of concomitant SARS-
CoV2 infection with a stroke diagnosis depending on
the frequency of testing at each site and across the
study period. The definition of the pandemic period
was arbitrary since the outbreak started and peaked
at different times at different locations. After adjust-
ment for peak COVID-19 volume for each country
and continent, the monthly volume declines were
retained for all stroke metrics (stroke hospitalization,
MT, ICH). As the penetration of MT remains limited
in many countries,17 some geographic regions were not
represented (i.e. central Africa). We did not collect data
on the timing or intensity of social distancing policies
including lockdown implementation across the different
localities which likely played an important role in the
reported stroke care decline. Finally, the sampling
varied with the availability of complete data in each
subset of the analysis.
Summary
There was a significant global decline in mechanical
thrombectomy and stroke admissions over the three
months studied during the pandemic. These decreases
were seen regardless of COVID-19 admission burden,
individual pre-pandemic stroke, and MT volumes.
Thus, it is critical to expeditiously raise public awareness
to prevent the additional healthcare consequences asso-
ciated with the lack of stroke treatment. These findings
can inform regional stroke networks preparedness29 in
the face of a future pandemic or anticipated surge of
COVID-19 cases in order to ensure that the access and
quality of stroke care remains preserved despite the
crises imposed by the continuous spread of the virus.
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Churojana142, Abdoreza Ghoreishi143, Mohammad
Saadatnia144, Ehsan Sharifipour145, Alice Ma146, Ken
Faulder146, Teddy Wu147, Lester Leung148, Adel Malek149,
Barbara Voetsch150, Ajay Wakhloo151, Rodrigo Rivera152,
Danny Moises Barrientos Iman153, Aleksandra Pikula154,
Vasileios-Arsenios Lioutas155, Gotz Thomalla156, Lee
Birnbaum157, Paolo Machi158, Gianmarco Bernava158,
Mollie McDermott159, Dawn Kleindorfer159, Ken Wong160,
Mary S.Patterson161, Jose Antonio Fiorot,Jr162, Vikram
Huded163, William Mack164, Matthew Tenser164, Clifford
Eskey165, Sumeet Multani166, Michael Kelly167, Vallabh
Janardhan168, Oriana Cornett169, Varsha Singh169, Yuichi
Murayama170, Maxim Mokin171, Pengfei Yang172, Xiaoxi
Zhang172, Congguo Yin173, Hongxing Han174, Ya Peng175,
Wenhuo Chen176, Roberto Crosa177, Michel Eli Frudit178,
International Journal of Stroke, 0(0)
8 International Journal of Stroke 0(0)
Jeyaraj D.Pandian179, Anirudh Kulkarni179, Yoshiki
Yagita180, Yohei Takenobu181, Yuji Matsumaru182, Satoshi
Yamada183, Ryuhei Kono184, Takuya Kanamaru185,
Hidekazu Yamazaki86, Manabu Sakaguchi187, Kenichi
Todo188, Nobuaki Yamamoto189, Kazutaka Sonoda190,
Tomoko Yoshida191, Hiroyuki Hashimoto192, Ichiro
Nakahara193, Elena Cora, MD194, David Volders194, Celina
Ducroux195, Ashkan Shoamanesh196, Johanna Ospel197,
Artem Kaliaev198, Saima Ahmed199, Umair Rashid199,
Leticia C. Rebello200, Vitor Mendes Pereira201, Robert
Fahed202, Michael Chen203, Sunil A Sheth204, Lina
Palaiodimou205, Georgios Tsivgoulis205, Ronil Chandra206,
Feliks Koyfman207, Thomas Leung208, Houman Khosravani
209, Sushrut Dharmadhikari210, Giovanni Frisullo,211, Paolo
Calabresi,211, Alexander Tsiskaridze,212, Nino Lobjanidze,212,
Mikayel Grigoryan,213, Anna Czlonkowska,214, Diana
Aguiar de Sousa,215, Jelle Demeestere216, Conrad Liang217,
Navdeep Sangha218, Helmi L. Lutsep219, Óscar Ayo-
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